Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

医学 彭布罗利珠单抗 内科学 肿瘤科 卵巢癌 临床研究阶段 癌症 妇科 化疗 免疫疗法
作者
Ursula A. Matulonis,Ronnie Shapira‐Frommer,Alessandro D. Santin,Alla Lisyanskaya,Sandro Pignata,Ignace Vergote,Francesco Raspagliesi,Gabe S. Sonke,Michael J. Birrer,Diane Provencher,Jalid Sehouli,Nicoletta Colombo,Antonio González-Martı́n,Ana Oaknin,Petronella B. Ottevanger,Vilius Rudaitis,Kianoosh Katchar,Huita Wu,Stephen J. O’Keefe,Jane Ruman
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:30 (7): 1080-1087 被引量:761
标识
DOI:10.1093/annonc/mdz135
摘要

ABSTRACT

Background

Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker.

Patients and methods

This phase II study of pembrolizumab (NCT02674061) examined two patient cohorts with ROC: cohort A received one to three prior lines of treatment with a platinum-free interval (PFI) or treatment-free interval (TFI) between 3 and 12months and cohort B received four to six prior lines with a PFI/TFI of ≥3months. Pembrolizumab 200mg was administered intravenously every 3weeks until cancer progression, toxicity, or completion of 2years. Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.

Results

Cohort A enrolled 285 patients; the first 100 served as the training set for PD-L1 biomarker analysis. Cohort B enrolled 91 patients. ORR was 7.4% for cohort A and 9.9% for cohort B. Median DOR was 8.2months for cohort A and not reached for cohort B. DCR was 37.2% and 37.4%, respectively, in cohorts A and B. Based on the training set analysis, CPS 1 and 10 were selected for evaluation in the confirmation set. In the confirmation set, ORR was 4.1% for CPS<1, 5.7% CPS ≥1, and 10.0% for CPS ≥10. PFS was 2.1months for both cohorts. Median OS was not reached for cohort A and was 17.6months for cohort B. Toxicities were consistent with other single-agent pembrolizumab trials.

Conclusions

Single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response.

Clinical Trial Number

Clinicaltrials.gov, NCT02674061
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
笨笨山芙的应助被JiaYouguo采纳,获得20
刚刚
ding的应助被jill采纳,获得10
刚刚
cx发布了新的文献求助10
1秒前
Jyy完成签到 ,获得积分10
1秒前
1秒前
轻松的冥王星完成签到,获得积分10
1秒前
匆匆发布了新的文献求助10
2秒前
2秒前
2秒前
plddd完成签到,获得积分10
2秒前
小宋完成签到,获得积分0
3秒前
3秒前
itsdeva发布了新的文献求助10
4秒前
gg发布了新的文献求助10
4秒前
4秒前
4秒前
三哥秦发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
ou发布了新的文献求助10
6秒前
zjy发布了新的文献求助10
6秒前
7秒前
7秒前
plddd发布了新的文献求助30
7秒前
森海完成签到,获得积分10
7秒前
8秒前
匆匆发布了新的文献求助10
8秒前
8秒前
9秒前
跳越光子发布了新的文献求助10
9秒前
张贵川完成签到 ,获得积分10
9秒前
霸气的小熊猫完成签到,获得积分20
9秒前
一品真意完成签到,获得积分10
10秒前
小蘑菇的应助被Derek采纳,获得10
10秒前
Lee发布了新的文献求助10
10秒前
April发布了新的文献求助10
11秒前
乐观碧彤发布了新的文献求助10
11秒前
开朗啤酒发布了新的文献求助10
11秒前
冰夜雨发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193729
求助须知:如何正确求助?哪些是违规求助? 9579876
关于积分的说明 21868333
捐赠科研通 7793519
什么是DOI,文献DOI怎么找? 3437414
关于科研通互助平台的介绍 2560856
邀请新用户注册赠送积分活动 2484216